Adult-Onset Vitelliform Detachment Unresponsive to Monthly Intravitreal Ranibizumab

A 72-year-old woman with decreased visual acuity secondary to an adult-onset vitelliform detachment was treated with three monthly intravitreal injections of 0.5 mg of ranibizumab. Treatment response was monitored by visual acuity and by the eye-tracking feature of the Heidelberg Spectralis spectral domain optical coherence tomography (Heidelberg Engineering, Inc., Carlsbad, CA). There was no improvement in functional or anatomic outcome after three monthly injections of ranibizumab. The eye-tracking feature of the spectral domain optical coherence tomography system was highly accurate in making comparisons between serial optical coherence tomography examinations.